Acquisition and Long-term Observation of Patients With Severe Allergic Reactions
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: not applicable, observational study.
- Who it may be relevant to
- Registry conditions: Anaphylaxis. Basic parameters: No limits · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- Germany
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Overview
The Anaphylaxis Registry aims to assess data in a standardized form about symptoms, triggers, cofactors and therapy management from patients who experienced an anaphylactic reaction. This should improve diagnosis and long-term management of these life-threatening allergic reactions.
Detailed description
A better understanding of the triggers and pathology of anaphylactic reactions could lead to a better diagnosis and prophylaxis to avoid the occurence of these life-threatening allergic reactions. This can be an advantage for affected persons regarding the their treatment and long-term management.
The Anaphylaxis Registry is an opportunity to gather these standardized data. The blood sampling is optional for the patient, however, it will contribute to the better understanding of the sensitization profile and possible mechanisms. Recent publications showed a correlation between an anaphylactic reaction and certain biomarkers. Those data will be validated in a larger number of population with identification of further biomarkers. It is presumed that certain genetic and epigenetic polymorphisms are abundant for patients who experienced an anaphylaxis.
To summarize, this study aims to contribute to a better understanding of the anaphylaxis in general, the diagnosis, and the prognosis with different severities. With the identification of a certain trigger, the obtained understanding may help to decrease the risk of or prevent future repeating reactions.
Interventions
- Other not applicable, observational study
Patients do not receive intervention; observational study
Primary outcome measures
- Influence of risk factors [Time frame: 10 years]
Secondary outcome measures (6)
- Epiphenomenon [Time frame: 10 years]
- Current use of adrenaline [Time frame: 10 years]
- Future use of adrenaline [Time frame: 10 years]
- Country-specific differences in anaphylaxis handling [Time frame: 10 years]
- Biomarkers [Time frame: 10 years]
- Epigenetics [Time frame: 10 years]
Eligibility criteria
Inclusion criteria
- Anaphylactic reaction within the past 12 months
Exclusion criteria
\-
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Observational model
- Case-only
Study locations
Germany · 1 center
- Charité - Universitätsmedizin Berlin — Berlin
Publications
- Almaci M, Treudler R, Breiding M, Kohli A, Lange L, Pfohler C, Vogelberg C, Worm M. Allergen immunotherapy-induced anaphylaxis: Data from the European Anaphylaxis Registry. Ann Allergy Asthma Immunol. 2025 Jun;134(6):724-730. doi: 10.1016/j.anai.2025.02.012. Epub 2025 Feb 22. PMID 39993472
Identifiers
NCT: NCT05210543 · Anaphylaxis Registry